Work

Supplementary Table S1 from The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma

Year: 2023

Type: supplementary-materials

Abstract: PF-06463922 is potent against ALK-mutated NB cell lines in vitro. Mean (n=3) IC50 values ({plus minus} SD) for crizotinib and PF-06463922 are listed for 10 NB cell lines harboring the indicated ALK aberrations, plus one NSCLC cell line (NCI-H3122). Fold increases in the IC50 values with crizotinib over those measured for PF-06463922 are also listed in the right-most column.

DOI: 10.1158/2159-8290.22531194.v1

Authors: Nicole R. Infarinato, Jin H. Park, Kateryna Krytska, Hannah T. Ryles, Renata Sano, Katherine M. Szigety, Yimei Li, Helen Y. Zou, Nathan V. Lee, Tod Smeal, Mark A. Lemmon, Yael P. Mossé

Language: English

Topic: Neuroblastoma Research and Treatments

Subfield: Neurology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362481381

Cites:

Cited by:

Related to: 10